Zoetis (NYSE:ZTS) Rating Increased to Buy at Wall Street Zen

Zoetis (NYSE:ZTS) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

A number of other equities research analysts also recently issued reports on the stock. Bank of America boosted their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, January 28th. Stifel Nicolaus cut their price target on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a report on Tuesday, November 18th. KeyCorp assumed coverage on Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating on the stock. Finally, UBS Group set a $136.00 price objective on Zoetis in a research report on Thursday, January 29th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $152.91.

Zoetis Trading Up 1.1%

Zoetis stock opened at $128.73 on Friday. Zoetis has a 52-week low of $115.25 and a 52-week high of $177.00. The company has a market cap of $54.34 billion, a P/E ratio of 21.38, a P/E/G ratio of 1.94 and a beta of 0.96. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The business has a 50-day simple moving average of $125.41 and a two-hundred day simple moving average of $134.80.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter last year, the firm posted $1.40 earnings per share. The firm’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts predict that Zoetis will post 6.07 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Halbert Hargrove Global Advisors LLC grew its holdings in Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares in the last quarter. Global Wealth Strategies & Associates bought a new position in shares of Zoetis during the fourth quarter worth $25,000. Prosperity Bancshares Inc purchased a new position in Zoetis during the fourth quarter valued at $25,000. Lodestone Wealth Management LLC bought a new stake in Zoetis in the 4th quarter valued at $30,000. Finally, KERR FINANCIAL PLANNING Corp purchased a new stake in Zoetis in the 3rd quarter worth $31,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.